A Phase I/II Study of Venetoclax in Combination With ASTX727 (Cedazuridine/Decitabine) in Treatment-Naïve High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1/2
- Enrollment
- 52 patients (estimated)
- Sponsors
- MD Anderson Cancer Center, MD Anderson Cancer Center
- Collaborators
- Genentech, Genentech, MD Anderson Cancer Center
- Tags
- BCL-2 Inhibitor, Chemotherapy, Hypomethylating Agents (HMA)
- Trial Type
- Treatment
- Last Update
- 3 weeks ago
- SparkCures ID
- 1494
- NCT Identifier
- NCT04655755
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.